Active Pharmaceutical Ingredients Market Research Report: Information By Manufacturing Process (Captive Manufacturing and Contract Manufacturing), Type of Synthesis (Synthetic and Biotech), By API Formulation (Generic API and Branded/Innovative API), Application (Cardiovascular Disease, Oncology, Neurological Disorders, Orthopedic Disorders, Respiratory, Gastrointestinal Disorders, Urology and others), Molecules (Large Molecule and Small Molecule) and Region - Forecast 2027
|ID: VPR/HC/1054||Publishing Year: December 2021||Pages: 118||Format:|
Active Pharmaceutical Ingredients Market Overview:
The rise in the rates of chronic diseases is a major driver of the Global Active Pharmaceutical Ingredients (API) Market. According to the WHO, "CVDs (Cardiovascular Diseases) are the leading cause of death worldwide: more people die each year from CVDs than from any other cause." CVDs claimed the lives of 17 million people worldwide in 2016, accounting for 31% of all deaths. Heart attacks and strokes accounted for 87 percent of these deaths.” Cancer claimed the lives of 9 million people in 2020, while Asthma, the most frequent chronic condition in children, claimed the lives of 422,000 people in 2019. The rising prevalence of various disorders necessitates the development of a wide range of pharmaceuticals to treat them, resulting in the growth of the Global Active Pharmaceutical Market. Another key growth factor is the global increase in the ageing population. In 2019, the United Nations reported that there were 705 million persons aged 65 and up around the world. With such a large elderly population, many chronic and acute disorders develop, necessitating the development of innovative pharmaceuticals to reduce their effects, resulting in an increase in the Global Active Pharmaceutical Ingredients (API) Market.
Key players in the Active Pharmaceutical Ingredients Market include Pfizer Inc. (US), Novartis International AG (Switzerland), Merck & Co. (US), Teva Pharmaceutical Industries Ltd. (Israel), Mylan N.V. (US), BoehringerIngelheim (Germany), F. Hoffmann-La Roche AG (Switzerland), Sanofi (France), AbbVie (US), Eli Lilly and Company (US), AstraZeneca (UK), Bristol-Myers Squibb (US), and GlaxoSmithKline plc (UK).
Throughout the predicted period, the rise of COVID-19 instances has played an important role in the development of active pharmaceutical component producers. In India's Active Pharmaceutical Ingredient Market, the government has completed a molecule-by-molecule charting of APIs supplied from China in order to boost domestic construction and imports from third-party providers in light of the COVID-19 pandemic's supply chain disruptions. The administration is also putting together special provisions for APIs that must still come from China.
The COVID-19 pandemic has added a new stumbling block, as countries throughout the world have decided to boycott APIs made in China. Several strategic Pharmaceutical Businesses' manufacturing and supply chains were hampered by the COVID-19 outbreak. The Worldwide Active Pharmaceutical Ingredient Business model is expected to be impacted significantly by China's reliance on APIs for various biologics and generic pharmaceuticals. During the Chinese government's pandemic lockdown measures, around 44 enterprises were deemed invalid.
Chronic diseases such as diabetes, coronary artery disease, chronic obstructive pulmonary disease (COPD), asthma, hepatitis, arthritis, and cancer have increased dramatically in key locations around the world over the previous few decades. This is due to a growing geriatric population around the world (by 2050, more than 20% of the worldwide population will be over 65 years old), changing lifestyles, and nutritional changes as a result of rapid urbanisation. According to the International Diabetes Federation, 463 million individuals were diagnosed with diabetes globally in 2019. Furthermore, by 2030, the number of new cancer cases is predicted to increase to 23.6 million each year. Aside from cancer, the prevalence of a variety of other diseases has risen.
One of the key issues faced by market competitors is the high manufacturing cost of APIs. To achieve compliance with standards such as the cGMP, manufacturers frequently have to make substantial investments in their manufacturing facilities. This includes renovating production facilities, familiarising employees with qualification standards and processes, and compiling a dossier of product efficacy and safety testing that meet regulatory requirements. Furthermore, the costs of acquiring regulatory clearances are more expensive for small businesses. API synthesis sometimes necessitates the use of expensive and unusual building blocks and raw materials, which adds to the expense of producing APIs.
The API Market is divided into several categories, including molecular type, manufacturer type, synthesis, chemical synthesis, medication type, utilisation, potency, and therapeutic application. The growth of segments allows you to study specific pockets of growth and market approaches, as well as establish your main application areas and target market differences.
The Active Pharmaceutical Ingredients (API) Industry is divided into two categories: small molecule and large molecule. Because of their high penetration potential, small molecules are predicted to dominate the Active Pharmaceutical Ingredients (API) Market in 2021, owing to an increasing number of regulatory approvals and expanding research & development on novel small molecules.
The Active Pharmaceutical Ingredients (API) Industry is divided into two types based on their type: novel active pharmaceutical Ingredients and Generic Active Pharmaceutical Ingredients. Because of the high cost of unique APIs compared to generic APIs and increased FDA approval for new molecular entities, the Innovative Active Pharmaceutical Ingredients segment is predicted to dominate the Active Pharmaceutical Ingredients (API) Market in 2021.
North America had the highest revenue share of 40 percent in 2020 and is predicted to hold that position throughout the forecast period. This might be linked to the rising epidemiology of cancer and other lifestyle-related disorders, which encourages R&D and hence boosts market growth.
During the forecast period, Asia Pacific is expected to have the highest CAGR of 8%. The existence of economies like China and India, which the world relies on for low-cost API production, is a benefit for the area. The industry is expected to develop due to rising healthcare expenditure in the region.
Over the projection period, Europe is expected to grow significantly. The market is likely to be driven by an increase in research funding and the local presence of key industry players in this region. Due to increased investments, the number of Biopharmaceutical Businesses in Europe is increasing.
Frequently Asked Questions
Type Here for table of content.